Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...

Untitled Document

BioCorRx, Inc. (BICX)

OTCQB-listed, BioCorRx, Inc. is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. It provides a unique approach to the treatment of substance abuse addiction and has its BioCorRx® Recovery Program. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program. BioCorRx's concentration is on improving the quality of life for recovering addicts. BioCorRx is based in Anaheim, California.

The BioCorRx® Recovery Program comprises two main components. The first component consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist, which can substantially decrease physical cravings for alcohol and opioids.

The second component is a one-on-one proprietary counseling program. It is particularly tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatments.

In addition, the company has expanded the support structure to include 12 months of a peer-support system using trained recovery specialists. Moreover, BioCorRx is developing a patent pending injectable form of naltrexone.

BioCorRx also has a research and development (R&D) subsidiary, BioCorRx Pharmaceuticals. Currently, this subsidiary is developing a new injectable naltrexone technology (BICX101) via a partnership with TheraKine Ltd.

BioCorRx's plan is to seek Food and Drug Administration (FDA) approval for BICX101 and/or its naltrexone implant product(s). BICX101 is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism.

Recently, BioCorRx announced a pilot for the BioCorRx® Recovery Program in collaboration with the One Day at a Time Program (ODAAT). This is a program funded by the City of Philadelphia and State of Pennsylvania.

This will be a paid demonstration pilot in which the BioCorRx Recovery Program will be utilized to treat a number of individuals suffering from opioid and alcohol use disorders. The ODAAT program assists greater than 56,000 residents of Philadelphia.

BioCorRx also recently announced that following the pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA), and based on the FDA's responses to BioCorRx's development plan for BICX102, it has extended Dr. Balbir S. Brar's agreement as VP of Drug Development for the BioCorRx Pharmaceuticals subsidiary for an additional one year period.

Dr. Brar has more than 25 years of experience in drug and device development. This includes international regulatory submissions for greater than 50 INDs, 510(k)s and 505(b)(2)s, and also approval of 8 NDAs for drugs now in the marketplace.

In addition, BioCorRx announced the results of its pre-IND meeting with the FDA. The FDA judged the 505(b)(2) pathway as an acceptable route for approval for BICX102. The 505(b)(2) pathway is intended to provide an abbreviated route to approval with less study requirements than traditional applications. BICX102 is a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.




The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.